The Cancer Research UK Oxford Centre is delighted to welcome Professor Amato J Giaccia (recently appointed as the new director of the MRC Oxford Institute for Radiation Oncology) to the Oxford cancer research community.
Professor Giaccia was recruited to the Institute for Radiation Oncology in Oxford after many successful years as director of the Division of Radiation & Cancer Biology at the University of Stanford, California. He is internationally recognised for his contribution to understanding the role of tumour microenvironment, hypoxia, and HIF-1-mediated pathways in cancer. He has more than 20 years of experience in Radiation Oncology research with over 200 publications, has been elected to the National Academy of Medicine, and has been honoured with the American Society of Therapeutic Radiation Oncology’s Gold Medal. He also co-authored the widely used textbook “Radiobiology for the Radiologist”.
His distinguished scientific career has garnered him an international standing within the global Radiation Oncology community which, with a wealth directorship experience and global perspective on cancer patient care, ideally places him to lead Oxford’s Radiation Oncology research community. Prof. Giaccia seeks to build on the Institute’s existing expertise, integrate novel multidisciplinary fundamental research across Oxford University, and work with Oxford’s commercial, governmental, academic and charitable partners to ensure that patients across the UK receive the most effective radiation therapy treatment to fight their individual cancer.
Professor Chris Schofield, Head of the Department of Chemistry, said: “It is absolutely brilliant to attract a scientist of Professor Giaccia’s calibre to Oxford. His work and expertise perfectly bridge Oxford’s outstanding basic research in cell biology and radiation oncology.”’
Professor Mark Middleton, Head of the Department of Oncology, said: ‘The Department of Oncology is excited that Professor Giaccia has agreed to join us at such a momentous time to help us secure the future of OIRO and the contribution it makes to the world of radiation oncology’.